Brain tumor immunotherapy: What have we learned so far?

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Van Gool, Stefaan Willy ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Dendritic cell vaccines; Galectin 1; Immunomodulation; Immunotherapy; Malignant glioma; Oncolytic viruses

Indexed keywords

EID: 84934268827     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00098     Document Type: Review

References (173)

1. Fleury A, Menegoz F, Grosclaude P, Daures JP, Henry Amar M, Raverdy N, et al. Descriptive epidemiology of cerebral gliomas in France. Cancer (1997) 79:1195-202. doi:10.1002/(SICI)1097-0142(19970315)79:6<1195::AID-CNCR19>3.0.CO;2-V.
2. Tamber MS, Rutka JT. Pediatric supratentorial high-grade gliomas. Neurosurg Focus (2003) 14. Available from: http://www.medscape.com/viewarticle/449870.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459-66. doi:10.1016/S1470-2045(09)70025-7.
5. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia (1995) 15:211-21. doi:10.1002/glia.440150303.
6. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 114:443-58. doi:10.1007/s00401-007-0293-7.
7. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 12:259-66. doi:10.1023/A:1008382516636.
8. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol (2013) 15:4-27. doi:10.1093/neuonc/nos273.
9. Greenspoon JN, Sharieff W, Hirte H, Overholt A, Devillers R, Gunnarsson T, et al. Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. Onco Targets Ther (2014) 7:485-90. doi:10.2147/OTT.S60358.
10. Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, et al. Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol (2013) 8:161. doi:10.1186/1748-717X-8-161.
11. Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg (2013) 118:812-20. doi:10.3171/2012.9.JNS1277.
12. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer (2005) 92:241-5. doi:10.1038/sj.bjc.6602321.
13. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J (2012) 18:40-4. doi:10.1097/PPO.0b013e318243f6c9.
14. De Fazio S, Russo E, Ammendola M, Donato Di PE, De Sarro G. Efficacy and safety of bevacizumab in glioblastomas. Curr Med Chem (2012) 19:972-81. doi:10.2174/092986712799320646.
15. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, Ceuppens JL, et al. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother (2005) 54:372-82. doi:10.1007/s00262-004-0615-8.
16. De Vleeschouwer S, Spencer L I, Ceuppens JL, Van Gool SW. Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells. J Neurooncol (2007) 84:131-40. doi:10.1007/s11060-007-9362-y.
17. Maes W, Deroose C, Reumers V, Krylyshkina O, Gijsbers R, Ceuppens J, et al. In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol (2009) 91:127-39. doi:10.1007/s11060-008-9691-5.
18. Maes W, Galicia Rosas G, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol (2009) 11:529-42. doi:10.1215/15228517-2009-004.
19. Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer (2014) 134:873-84. doi:10.1002/ijc.28426.
20. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, et al. Transient local response and persistent tumor control of recurrent malignant glioma treated with combination therapy including dendritic cell therapy. J Neurosurg (2004) 100:492-7.
21. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer (2004) 91:1656-62. doi:10.1038/sj.bjc.6602195.
22. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 14:3098-104. doi:10.1158/1078-0432.CCR-07-4875.
23. Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, Rutkowski S, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer (2010) 54:519-25. doi:10.1002/pbc.22319.
24. Elens I, De Vleeschouwer S, Pauwels F, Van Gool SW. Resection and immunotherapy for recurrent grade III glioma. ISRN Immunol (2012) 2012:1-9. doi:10.5402/2012/530179.
25. De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, Van Loon J, et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother (2012) 61:2105-12. doi:10.1007/s00262-012-1271-z.
26. Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, et al. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy (2014) 16:946-64. doi:10.1016/j.jcyt.2014.02.017.
27. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol (2010) 99:261-72. doi:10.1007/s11060-010-0131-y.
28. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother (2012) 61:2033-44. doi:10.1007/s00262-012-1261-1.
29. Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S, et al. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology (2011) 53:721-31. doi:10.1007/s00234-010-0802-6.
30. Van Cauter S, Veraart J, Sijbers J, Peeters RR, Himmelreich U, De Keyzer F, et al. Gliomas: diffusion kurtosis MR imaging in grading. Radiology (2012) 263:492-501. doi:10.1148/radiol.12110927.
31. Van Cauter S, Sima DM, Luts J, Ter BL, Ribbens A, Peeters RR, et al. Reproducibility of rapid short echo time CSI at 3 Tesla for clinical applications. J Magn Reson Imaging (2013) 37:445-56. doi:10.1002/jmri.23820.
32. Van Cauter S, De Keyzer F, Sima DM, Croitor Sava A, D'Arco F, Veraart J, et al. Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas. Neuro Oncol (2014) 16(7):1010-21. doi:10.1093/neuonc/not304.
33. De Vleeschouwer S, Van Gool SW, Van Calenbergh F. Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells. Childs Nerv Syst (2005) 21:7-18. doi:10.1007/s00381-004-0994-3.
34. De Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, Van Gool S, et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery (2006) 59:988-99. doi:10.1227/01.NEU.0000245595.38957.3E.
35. Van Gool SW, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high grade gliomas. Brain Pathol (2009) 19:694-712. doi:10.1111/j.1750-3639.2009.00316.x.
36. Verschuere T, De VS, Lefranc F, Kiss R, Van Gool SW. Galectin-1 and immunotherapy for brain cancer. Expert Rev Neurother (2011) 11:533-43. doi:10.1586/ern.11.40.
37. Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother (2011) 60:153-60. doi:10.1007/s00262-010-0946-6.
38. Van Gool S, De Vleeschouwer S. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients? Expert Rev Neurother (2012) 12:1173-6. doi:10.1586/ern.12.107.
39. Vandenberk L, Van Gool SW. Treg infiltration in glioma: a hurdle for antiglioma immunotherapy. Immunotherapy (2012) 4:675-8. doi:10.2217/imt.12.64.
40. Jadavji NM, Deng L, Leclerc D, Malysheva O, Bedell BJ, Caudill MA, et al. Severe methylenetetrahydrofolate reductase deficiency in mice results in behavioral anomalies with morphological and biochemical changes in hippocampus. Mol Genet Metab (2012) 106:149-59. doi:10.1016/j.ymgme.2012.03.020.
41. Marsh JC, Goldfarb J, Shafman TD, Diaz AZ. Current status of immunotherapy and gene therapy for high-grade gliomas. Cancer Control (2013) 20:43-8.
42. Jackson C, Ruzevick J, Brem H, Lim M. Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy (2013) 5:155-67. doi:10.2217/imt.12.155.
43. Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev (2013) 39:891-907. doi:10.1016/j.ctrv.2013.05.007.
44. Cao JX, Zhang XY, Liu JL, Li D, Li JL, Liu YS, et al. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One (2014) 9:e107173. doi:10.1371/journal.pone.0107173.
45. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol (2001) 19:47-64. doi:10.1146/annurev.immunol.19.1.47.
46. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (1990) 249:918-21. doi:10.1126/science.2392683.
47. Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation ofcytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHCclass I presentation pathway. J Immunol (1996) 156:3721-6.
48. Clarke SR. The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukoc Biol (2000) 67:607-14.
49. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 179:1215-24. doi:10.1084/jem.179.4.1215.
50. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer (2004) 109:893-9. doi:10.1002/ijc.20050.
51. Basse PH, Whiteside TL, Chambers W, Herberman RB. Therapeutic activity of NK cells against tumors. Int Rev Immunol (2001) 20:439-501. doi:10.3109/08830180109054416.
52. Anguille S, Smits EL, Lion E, Van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 15:e257-67. doi:10.1016/S1470-2045(13)70585-0.
53. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39:38-48. doi:10.1016/j.immuni.2013.07.004.
54. Yi H, Appel S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand J Immunol (2013) 78:167-71. doi:10.1111/sji.12060.
55. Kalinski P, Muthuswamy R, Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines (2013) 12:285-95. doi:10.1586/erv.13.22.
56. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 20:5620-9. doi:10.1158/1078-0432.CCR-14-0832.
57. Wu ZB, Qiu C, Zhang AL, Cai L, Lin SJ, Yao Y, et al. Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. J Immunol Res (2014) 2014:131494. doi:10.1155/2014/131494.
58. Schuessler A, Walker DG, Khanna R. Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment. Oncoimmunology (2014) 3:e29381. doi:10.4161/onci.29381.
59. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother (1998) 46:82-7. doi:10.1007/s002620050465.
60. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 28:4722-9. doi:10.1200/JCO.2010.28.6963.
61. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 18:5460-70. doi:10.1158/1078-0432.CCR-11-3368.
62. Wang J, Liao L, Tan J. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials. Immunotherapy (2012) 4:1031-42. doi:10.2217/imt.12.107.
63. Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 181:1383-90. doi:10.1164/rccm.200909-1465OC.
64. Van Tendeloo VF, Van De Velde AL, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 107:13824-9. doi:10.1073/pnas.1008051107.
65. Coosemans A, Wolfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, et al. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res (2010) 30:3709-14.
66. Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman ZN, et al. Wilms' tumor gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res (2013) 33:5495-500.
67. Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, et al. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res (2013) 33:3855-9.
68. Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, et al. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control (2013) 20:7-16.
69. Thurner B, Roder C, Dieckmann D, Heuer H, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods (1999) 223:1-15. doi:10.1016/S0022-1759(98)00208-7.
70. Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol (2003) 58:578-86. doi:10.1046/j.1365-3083.2003.01333.x.
71. Sorg RV, Ozcan Z, Brefort T, Fischer J, Ackermann R, Muller M, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother (2003) 26:374-83. doi:10.1097/00002371-200307000-00010.
72. Tuyaerts S, Noppe SM, Corthals J, Breckpot K, Heirman C, De Greef C, et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods (2002) 264:135-51. doi:10.1016/S0022-1759(02)00099-6.
73. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol (1996) 6:275-88. doi:10.1111/j.1750-3639.1996.tb00855.x.
74. Huber AK, Duncker PC, Irani DN. Immune responses to non-tumor antigens in the central nervous system. Front Oncol (2014) 4:328. doi:10.3389/fonc.2014.00328.
75. Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery (2012) 71:201-22. doi:10.1227/NEU.0b013e31824f840d.
76. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal-calf serum-free conditions. Eur J Immunol (1997) 27:3135-42. doi:10.1002/eji.1830271209.
77. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 24:677-88. doi:10.1016/j.immuni.2006.06.002.
78. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, et al. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother (2006) 55(3):254-67.
79. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today (1999) 20:561-7. doi:10.1016/S0167-5699(99)01547-9.
80. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 100:1354-61. doi:10.1182/blood-2001-11-0017.
81. Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood (2006) 108:228-37. doi:10.1182/blood-2005-08-3507.
82. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity (2003) 19:5-8. doi:10.1016/S1074-7613(03)00182-1.
83. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol (2003) 171:6275-82. doi:10.4049/jimmunol.171.11.6275.
84. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 174:2476-80. doi:10.4049/jimmunol.174.5.2476.
85. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol (2006) 176:157-64. doi:10.4049/jimmunol.176.1.157.
86. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 204:1441-51. doi:10.1084/jem.20070021.
87. Berger TG, Strasser E, Smith R, Carste C, Schuler-Thurner B, Kaempgen E, et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods (2005) 298:61-72. doi:10.1016/j.jim.2005.01.005.
88. Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology (2005) 114:204-12. doi:10.1111/j.1365-2567.2004.02076.x.
89. Dohnal AM, Graffi S, Witt V, Eichstill C, Wagner D, Ul-Haq S, et al. Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. J Cell Mol Med (2009) 13:125-35. doi:10.1111/j.1582-4934.2008.00304.x.
90. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol (2013) 52:147-52. doi:10.3109/0284186X.2012.692882.
91. Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, Sorg RV. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg (2006) 105:41-50. doi:10.3171/jns.2006.105.1.41.
92. Petrini B, Andersson B, Strannegard O, Wasserman J, Blomgren H, Glas U. Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. In vivo (1992) 6:531-4.
93. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A (2002) 99:931-6. doi:10.1073/pnas.022634999.
94. Pritchard-Jones K, Spendlove I, Wilton C, Whelan J, Weeden S, Lewis I, et al. Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br J Cancer (2005) 92:1358-65. doi:10.1038/sj.bjc.6602500.
95. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2011) 13:324-33. doi:10.1093/neuonc/noq157.
96. North RJ. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother (1984) 16:175-81. doi:10.1007/BF00205425.
97. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 10:5316-26. doi:10.1158/1078-0432.CCR-04-0497.
98. Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) 24:5226-34. doi:10.1038/sj.onc.1208519.
99. Mirimanoff RO, Gorlia T, Mason W, van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 24:2563-9. doi:10.1200/JCO.2005.04.5963.
100. Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rossler K, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet (2006) 166:46-55. doi:10.1016/j.cancergencyto.2005.08.021.
101. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci (2009) 100:2235-41. doi:10.1111/j.1349-7006.2009.01308.x.
102. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 360:765-73. doi:10.1056/NEJMoa0808710.
103. Verschuere T, van WM, Fieuws S, Lefranc F, Mathieu V, Kiss R, et al. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neurooncol (2013) 115:9-17. doi:10.1007/s11060-013-1201-8.
104. Alkassar M, Gartner B, Roemer K, Graesser F, Rommelaere J, Kaestner L, et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J Neurooncol (2011) 104:715-27. doi:10.1007/s11060-011-0606-5.
105. Koks CA, Garg AD, Ehrhardt M, Riva M, De Vleeschouwer S, Agostinis P, et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer (2014) 136:e313-25. doi:10.1002/ijc.29202.
106. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 68:5955-64. doi:10.1158/0008-5472.CAN-07-5973.
107. Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol (2012) 746:53-76. doi:10.1007/978-1-4614-3146-6_5.
108. Ahn BJ, Pollack IF, Okada H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel) (2013) 5:1379-412. doi:10.3390/cancers5041379.
109. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 8:234-43. doi:10.1215/15228517-2006-006.
110. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, Wesseling P, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 225:195-9. doi:10.1016/j.jneuroim.2010.05.020.
111. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol (2006) 8:261-79. doi:10.1215/15228517-2006-008.
112. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol (1997) 159:4415-25.
113. Roszman TL, Brooks WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol (1980) 39:395-402.
114. Maes W, Verschuere T, Van HA, Boon L, van GS. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin Dev Immunol (2013) 2013:952469. doi:10.1155/2013/952469.
115. Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol (2011) 89:130-42. doi:10.1038/icb.2010.70.
116. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2011) 186:807-15. doi:10.4049/jimmunol.1001483.
117. Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2008) 57:123-31. doi:10.1007/s00262-007-0336-x.
118. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 66:3294-302. doi:10.1158/0008-5472.CAN-05-3773.
119. Ardon H, Verbinnen B, Maes W, Beez T, Van Gool S, De Vleeschouwer S. Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination. J Immunol Methods (2009) 352(1-2):169-73. doi:10.1016/j.jim.2009.10.007.
120. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, et al. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1:326-33. doi:10.4161/onci.18852.
121. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol (2006) 27:387-93. doi:10.1016/j.it.2006.06.005.
122. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 309:1380-4. doi:10.1126/science.1113401.
123. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother (2009) 58:1627-34. doi:10.1007/s00262-009-0671-1.
124. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol (2010) 17:143-53. doi:10.1128/CVI.00292-09.
125. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer (2013) 133(1):98-107. doi:10.1002/ijc.27990.
126. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 14:6674-82. doi:10.1158/1078-0432.CCR-07-5212.
127. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother (2010) 33:991-8. doi:10.1097/CJI.0b013e3181f4c208.
128. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 111:5610-20. doi:10.1182/blood-2007-02-075945.
129. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther (2010) 18:1233-43. doi:10.1038/mt.2010.34.
130. Akasaki Y, Kikuchi T, Irie M, Yamamoto Y, Arai T, Tanaka T, et al. Cotransfection of poly(I: C) and siRNA of IL-10 into fusions of dendritic and glioma cells enhances antitumor T helper type 1 induction in patients with glioma. J Immunother (2011) 34:121-8. doi:10.1097/CJI.0b013e3181e5c278.
131. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1174:99-106. doi:10.1111/j.1749-6632.2009.04939.x.
132. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 112:610-8. doi:10.1182/blood-2008-01-135319.
133. de Vries IJ, Castelli C, Huygens C, Jacobs JF, Stockis J, Schuler-Thurner B, et al. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res (2011) 17:841-8. doi:10.1158/1078-0432.CCR-10-2227.
134. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother (2012) 61:629-41. doi:10.1007/s00262-011-1081-8.
135. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2007) 56:641-8. doi:10.1007/s00262-006-0225-8.
136. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 33:369-83. doi:10.1007/s00281-011-0245-0.
137. Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer (2012) 131(5):E670-80. doi:10.1002/ijc.27388.
138. Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer (2011) 11:505. doi:10.1186/1471-2407-11-505.
139. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother (2011) 61(3):353-62. doi:10.1007/s00262-011-1106-3.
140. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2011) 71:661-5. doi:10.1158/0008-5472.CAN-10-1259.
141. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res (2012) 32:5363-9.
142. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2013) 62(1):171-82. doi:10.1007/s00262-012-1322-5.
143. Moraes-Fontes MF, Rebelo M, Caramalho I, Zelenay S, Bergman ML, Coutinho A, et al. Steroid treatments in mice do not alter the number and function of regulatory T cells, but amplify cyclophosphamide-induced autoimmune disease. J Autoimmun (2009) 33:109-20. doi:10.1016/j.jaut.2009.03.008.
144. Available from: http://ec.europa.eu/health/files/advtherapies/2014_atmp/atmp_en.pdf.
145. Polyzoidis S, Keyoumars A. DCVax(R)-L-developed by northwest biotherapeutics. Hum Vaccin Immunother (2014) 10(11):3139-45. doi:10.4161/hv.29276.
146. Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines-hope or hype? Nat Rev Immunol (2014) 14:705-11. doi:10.1038/nri3727.
147. Sehgal K, Dhodapkar KM, Dhodapkar MV. Targeting human dendritic cells in situ to improve vaccines. Immunol Lett (2014) 162(1 Pt A):59-67. doi:10.1016/j.imlet.2014.07.004.
148. Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, Jouben-Steele L, et al. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides: case report. Neurosurg Focus (2000) 9(6):e8. doi:10.3171/foc.2000.9.6.9.
149. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 61:842-7.
150. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother (2001) 50:337-44. doi:10.1007/s002620100205.
151. Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, Maixner W, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol (2004) 6:236-46. doi:10.1215/S1152851703000668.
152. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 11:5515-25. doi:10.1158/1078-0432.CCR-05-0464.
153. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med (2007) 5:67. doi:10.1186/1479-5876-5-67.
154. Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci (2008) 15:114-21. doi:10.1016/j.jocn.2007.08.007.
155. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 359:539-41. doi:10.1056/NEJMc0804818.
156. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther (2009) 8:2773-9. doi:10.1158/1535-7163.MCT-09-0124.
157. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One (2012) 7:e32614. doi:10.1371/journal.pone.0032614.
158. Lasky JL III, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res (2013) 33:2047-56.
159. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother (2013) 62(9):1499-509. doi:10.1007/s00262-013-1453-3.
160. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, et al. Alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer (2012) 12:623. doi:10.1186/1471-2407-12-623.
161. Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology (2013) 2:e23401. doi:10.4161/onci.23401.
162. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 89:1172-9. doi:10.1038/sj.bjc.6601268.
163. Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, Zhang W, et al. Thymic CD8(+) T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol (2003) 171:4927-33. doi:10.4049/jimmunol.171.9.4927.
164. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 64:4973-9. doi:10.1158/0008-5472.CAN-03-3505.
165. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (2004) 27:452-9. doi:10.1097/00002371-200411000-00005.
166. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res (2005) 11:4160-7. doi:10.1158/1078-0432.CCR-05-0120.
167. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol (2011) 29:330-6. doi:10.1200/JCO.2010.30.7744.
168. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci (2011) 18:1048-54. doi:10.1016/j.jocn.2010.11.034.
169. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 34:382-9. doi:10.1097/CJI.0b013e318215e300.
170. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys (2012) 62:91-9. doi:10.1007/s12013-011-9265-6.
171. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy (2012) 14(6):733-42. doi:10.3109/14653249.2012.666633.
172. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg (2011) 77(5-6):736-44. doi:10.1016/j.wneu.2011.08.020.
173. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2013) 62:125-35. doi:10.1007/s00262-012-1319-0.